‘BUILDING BSL-3 FACILITY FOR COVAXIN DRUG SUBSTANCE MANUFACTURING’

“The company, along with Gujarat Biotechnology Research Centre (GBRC) has entered into a licensing agreement with Bharat Biotech to manufacture the drug substance for COVAXIN. We are currently building the BSL-3 facility suitable for manufacturing the drug substance for COVAXIN. The project is progressing well as per the timeline to manufacture up to 7 million doses per month. The development of vaccines against Classical Swine Fever (CSF), Lumpy Skin Disease (LSD) and Sheep Pox is going as per the timeline and the commercial production is expected to start by Q1FY23. Further, creation of additional infrastructure for bulk antigen production for animal vaccines is ongoing, with completion expected in Q4FY22, along with creation of a state-of-the-art fill-finish line for animal vaccines, with completion expected in Q3FY23. This expansion will double our existing capacity of 4.8 billion doses a year for veterinary vaccines.”

- RAJIV GANDHI,

Chief Executive Officer and Managing Director, Hester Biosciences, Ahmedabad